Among the 11 NSCLC patients included, 3 (27%) had PR and 7 (64%) has disease control and this percentage was higher among KRAS inhibitor naïve patients (75% PR and 100% disease control). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.